Vici grant for Michiel Vermeulen Reading the epitranscriptome15 April 2021
Michiel Vermeulen, theme Cancer development and immune defense, has been awarded a Vici grant from the Netherlands Organisation for Scientific Research (NWO), one of the largest personal scientific awards in the Netherlands.
Genetische pleister ‘remt’ blindheid in patiënten met Usher syndroom Leidse ProQR bouwt onderzoek Radboudumc verder uit14 April 2021
Het Leidse biotechbedrijf ProQR Therapeutics presenteerde deze week positieve resultaten van een klinische fase I/II studie met het molecuul QR-421a, een molecuul dat in de vroegste fase is ontwikkeld door onderzoekers van het Radboudumc
Assessment of research with material from an existing biobank.28 January 2021
If you want to perform research with material from a biobank and the initiation of this biobank has already been approved by the CMO Radboudumc, you only need to submit an application to the CMO Radboudumc for assessment in certain cases.
Financial regulation for sub-biobanks15 September 2020
Sub-biobanks are not required to pay up-front for the processing and storage of biomaterials. The effectiveness of this pre-financing agreement however is dependent on adherence to the demands regarding delivery and processing according to the Radboud Biobank standard operating procedures.
Opt-out versus Opt-In Consent for Residual Samples17 October 2019
The Radboud Biobank will be conducting a 6-month feasibility study, as proposed by the Netherlands Federation of University Medical Centers (NFU), to evaluate the impact of migrating to a opt-in method, which requires explicit consent from the patient for use of the residual material.